- Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial2019 | First Faculty of Medicine
- Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod2018 | First Faculty of Medicine
